Three decades of p53 research have led to many advances in understanding the basic biology of normal and cancer cells. Nonetheless, the detailed functions of p53 in normal cells, and even more so in cancer cells, remain obscure. A major breakthrough is the realization that mutant p53 has a life of its own: it contributes to cancer not only through loss of activity, but also through gain of specific 'mutant functions'. This new focus on mutant p53 is the rationale behind the meeting series dedicated to advances on mutant p53 biology. This review provides an overview of results presented at the Fourth International Workshop on Mutant p53, held in Akko, Israel in March 2009. New roles and functions of p53 relevant for tumor suppressions were presented, including the regulation of microRNAs networks, the modulation of cell-stroma interactions and the induction of senescence. A main focus of the meeting was the rapidly growing body of knowledge on autonomous properties of mutant p53 and on their oncogenic 'gain of function' impact. Importantly, the meeting highlighted that, 30 years after p53 discovery, research on mutant p53 is entering the clinical and translational era. Two major steps forward in this respect are a better understanding of the active mechanism of small drugs targeting mutant p53 in tumor cells and an improved definition of the prognostic and predictive value of mutant p53 in human cancer.
Introduction
The p53 tumor suppressor protein, encoded by the TP53 gene (OMIM 191170) , lies at the center of an elaborated circuit controlling cell proliferation and interconnecting with many cellular functions. In response to various forms of stress, p53 is activated and accumulates in the nucleus, where it regulates the transcription of numerous target genes using specific DNA response elements. From the p53 activation, several biological responses occur including apoptosis, cell cycle arrest, DNA repair, differentiation or senescence. The nature of the p53-induced response depends on the type of stress and cell/tissue in which it occurs. Beyond its nuclear role, p53 regulates some mitochondrial functions. Thus, p53 is the archetype of a truly multifunctional protein, in which a small number of structural domains is specifically involved in vast arrays of complex interactions with various species (DNA, RNA, proteins and cell metabolites).
The TP53 gene is often mutated in cancer with a high proportion of missense mutations, leading to the production of a protein expressed at high levels that differs from wild-type p53 by just one amino acid residue. This feature is a characteristic of p53, as many 'classical' suppressor genes, such as APC or BRCA1, are mainly altered through nonsense or frameshift mutations leading to the expression of inactive truncated proteins. In the few years following the p53 discovery in 1979, it was reported that missense mutant p53 might exert some oncogenic function (or gain of function (GOF)). In particular, they can cooperate with oncogenes, such as Ras, to transform primary rodent fibroblasts. For more than a decade, the most convincing observation supporting a GOF has been that mutant p53 is often expressed at high levels throughout tumor progression stages, even in distant metastases. Soon after the elucidation of the main mechanisms controlling wild-type p53 in the 1990s, the hunt for mutant p53 functions became a major goal in cancer research. Today, a large body of knowledge has accumulated on mutant p53 GOF, which appears as a major contender in human cancer. We summarize here some of the recent trophies of the hunt for mutant p53 functions, which were presented at the Fourth International Workshop on Mutant p53 (Akko, Israel (http:// www-p53.iarc.fr/P53meeting2009/P53meeting2009.html)). Lecture numbers available on following link: (http:// www-p53.iarc.fr/p53meeting2009/Abstracts.html).
Modulation of p53 activity
Importance of DNA sequence and structure to p53 binding abilities In response to stress, accumulation of p53 results in its binding as a tetramer to DNA in a sequence-specific manner. Initial in vitro studies identified a p53 consensus response element (p53RE), which consists of a palindromic sequence composed of two halves, each one consisting of a sequence matching the consensus RRRCWWGYYY (R: purine; W: A or T; Y: pyrimidine), separated by a spacer (n) from 0 to 13 nucleotides of any type 1 ( Figure 1 ). This symmetric DNA motif is consistent with the binding of a tetramer: two monomers bind each side of the motif forming a 'grip' over the double helix. However, several non-canonical p53REs have been described within the genome, indicating that p53 may have broader binding capacities. Using two different approaches, Shakked and Resnick demonstrated that p53 transcriptional activity was dependent on both the length and the nucleotide sequence of the spacer (Figure 1 ). Shakked (L14) presented high resolution crystal structures of the p53 core domain bound to different p53RE oligonucleotides. 2 DNA with contiguous half sites (n ¼ 0) showed a local change in the DNA double helix associated with a rearrangement of the four p53 monomers. This configuration resulted in increased protein-protein and protein-DNA interactions and hence higher binding affinity as compared with oligonucleotides carrying a spacer (nX1). These data suggest that the presence of a spacer may be associated with decreased affinity of p53 for its p53RE. Resnick (L9) made the same observation using a diploid yeast system, expressing p53 under the control of a galactose-dependent promoter and a reporter gene driven by p53RE. 3 In this system, increasing the number of spacer nucleotides resulted in a drastic decrease of both p53 transcriptional and DNA binding activities. He also showed that conservation of the p53RE core motif (CWWG) is the main requirement for the definition of a half site, the CATG motif appearing to be the most efficient one. In addition, half-and three-quarter-sites could be used in yeast and human cells, such as in the VEGF and RAP80 genes. In the VEGF promoter, the second half site is constituted by an estrogen-receptor binding element, while in RAP80, the half site becomes active only under exposure to UV. 4, 5 These observations indicate that p53 transcriptional activity may be much more complex than previously expected, with interplays between p53 and other transcription factors favored by the proximity of their DNA binding sites.
The role of p53 acetylation with respect to DNA binding has been highlighted by Prives (L7). Indeed, she reported that unacetylated p53 binds to its p53REs only when these REs are present as naked DNA, for example within the linker region between nucleosomes, although p53 acetylation may increase the scope and the availability of sites within nucleosomal DNA.
Re-evaluation of p53 post-translational modifications Post-translational modifications of p53 such as phosphorylation, acetylation or sumoylation have been shown to be essential in determining and regulating p53 activity in vitro. However, their effects in vivo remain difficult to assess. Sabapathy (S1) generated a 'knock-in' mouse strain replacing the serine 312 residue, equivalent to the human serine 315, by alanine (S312A) to abolish phosphorylation. This residue has been proposed to have a role in the regulation of p53 protein stability. [6] [7] [8] [9] p53
S312A/S312A knock-in mice are viable, fertile and notpre-disposed to spontaneous tumor formation. In addition, the p53 S312A protein was found to be activated as efficiently as wild-type p53 and its turnover rate was not affected, suggesting that despite in vitro evidence this phosphorylation event may not be critical for in vivo suppressive functions.
It is well established that wild-type p53 is extensively modified on several lysine residues and that these modifications are relevant to its function. 10 Prives (L7) has used the p53-null lung cancer cell line H1299 to generate clones expressing inducible p53 variants, in which the two lysines located within the p53 tetramerization domain, K351 and K357, were changed either to arginine (R, to conserve the negative charge), or to glutamine (Q, to neutralize the charge and possibly mimic acetylation). p53 K351R/K357R cells displayed similar DNA binding, transcriptional abilities and cell cycle arrest capacities than wild-type p53 cells. On the other hand, p53 K351Q/K357Q was selectively and transcriptionally impaired and could not induce cell cycle arrest even though its expression led to higher levels of p21 than wildtype p53. Additionally, recent reports have shown that K357 can be acetylated and that K351 is mutated in cancer cells. [11] [12] [13] These findings provide clues for a role of acetylation in regulating p53 tetramerization.
Identification of a natural p53 antisense transcript
Recently, a new post-transcriptional mechanism has been implicated in the modulation of p53 function. A natural antisense transcript of p53, termed Wrap53, was identified by Farnebo in Wiman's group (L18) that may modulate p53 activity.
14 The WRAP53 gene is located on the Figure 1 p53RE structure and p53 transactivation activity. The p53 protein binds specifically to DNA within gene promoters or introns through p53REs, which are composed of two palindromic half sites (R ¼ purine; W ¼ A/T; P ¼ pyrimidine) separated by spacers composed of 0-13 nucleotides (n). Shakked and Resnick reported that p53 DNA binding and transcriptional activities can be modulated by the nature of the p53RE core motif (CWWG), as well as length of spacer (n), the most efficient p53RE corresponding to the presence of the CATG core motif and the absence of any spacer (n ¼ 0).
Understanding wild-type and mutant p53 activities in human cancer I Goldstein et al 17p13.1 locus and is transcribed in the opposite direction to TP53, the proximal part of Wrap53 mRNA overlapping with the non-coding exon 1 and part of the long intron 1 of p53 mRNA ( Figure 2 ). Thus, Wrap53 transcripts anneal with p53 transcripts leading to p53 accumulation at both mRNA and protein levels in basal conditions, although Wrap53 silencing resulted in decreased accumulation of p53 upon DNA damage. These observations suggest that this antisense transcript may represent a novel and important regulator of p53 function, although its effect on mutant p53 activities remains to be investigated.
The p53 pathway: from normal to tumor cells
Expanding the range of tumor suppressive functions of the p53 pathway Normal cells have a limited dividing capacity in vitro, reaching a state of senescence in which the capability to replicate is irreversibly lost. Oncogene activation or genotoxic stress may also induce a senescent state, which has a role in tumor suppression and is regulated by p53. 15, 16 p53-induced senescence involves the activation of specific microRNA targets, such as members of the miR-34 family (a-c). Harris (L1) showed that Nutlin-induced cellular senescence in normal human fibroblasts is p53-dependent and correlates with elevated miR-34s expression. 17 When fibroblasts were treated with antisense miR-34a, they extended their replicative capacity by three population doublings. Additionally, Nutlin-induced senescence was significantly impaired by oligonucleotide-mediated knock down of endogenous miR-34a. 18 With the emergence of cancer stem cells as the critical source of cell populations during carcinogenesis, it is essential to determine how p53 functions participate in the control and maintenance of normal and cancer stem cell status. Tolstonog (L4) presented new results exploring the role of p53 in controlling the proliferation and differentiation of stem/progenitor cells. Mouse F9 teratocarcinoma cells were used, a well-described model system for embryo-derived cancer cell differentiation. In culture, F9 cells are heterogeneous and contain mixed populations of stem and committed progenitor cells. Stem/progenitor cells can be identified on the basis of their high expression of aldehyde dehydrogenase. It turned out that ALDE þ cells also contain high p53 levels, suggesting a role for p53 in controlling stemness. One mechanism by which p53 may influence this process, is the regulation of asymmetric cell division, a hallmark of stemness. Stem/progenitor cells devoid of tight control over cell fate regulation are prone to expansion via symmetric cell divisions. These results support recent studies showing a role for p53 in embryonic stem cell differentiation and apoptosis. [19] [20] [21] [22] MdmX, also termed Mdm4, is a Mdm2 homologue that has been shown to inhibit p53 activity during embryonic development. Its uncontrolled overexpression may drive oncogenic transformation. 23, 24 A study presented by de Lange (S3) indicated that MdmX is highly expressed in a subset of uveal melanoma cell lines. As TP53 mutations are uncommon in uveal melanoma the hypothesis arose that MdmX may be overexpressed in this cancer to inactivate the p53 pathway. Uveal melanoma cell lines with high MdmX expression were used. Knock down of MdmX significantly impaired cell growth and induced apoptosis. These effects appeared to be at least partially p53-independent. This study, together with previous reports, 25, 26 suggests a role of MdmX that stretches beyond p53 inhibition.
p53, an important key in the carcinogenic process The process of carcinogenesis involves sequential accumulation of genetic alterations causing loss of tumor suppressor genes and overactivation of oncogenes. To overcome genetic variations that epitomize cancerderived cell lines, Rotter (L8) has established an in vitro transformation model, in which diploid human fibroblasts WI-38 were immortalized by the introduction (1) of the telomerase catalytic subunit hTERT, (2) of the p53 dominant negative peptide GSE56, which inactivates p53 and (3) of the oncogenic H-Ras V12 . In this protocol, it appeared that, only INK4A-deficient cells expressing H-Ras V12 and GSE56 peptide became fully transformed and could form tumors in nude mice. Genome-wide microarray analysis revealed several stable genetic signatures associated with the carcinogenic process. A 'Cancerrelated Gene Signature' (CGS), which mainly consisted of inflammatory chemokines, cytokines, interleukins and extracellular matrix related proteins, 27, 28 was upregulated when both H-Ras V12 and the p53 dominant-negative peptide GSE56 were concomitantly expressed in the cells. Wild-type p53 repressed CGS expression by mechanisms involving the p53 targets BTG2 and ATF3, previously described as involved in Ras-induced transformation. 29, 30 ATF3 directly binds to the CGS promoters and represses their expression, while BTG2 interacts with H-Ras and represses its activity. 31 This effect may represent a novel suppressive function of wild-type p53. These findings are supported by reports showing that pro-malignant genes are upregulated following p53 loss and acquisition of activated Ras. 32, 33 Crosstalk between tumor cells and their microenvironment are critical for tumor formation and progression. Figure 2 Wrap53, a natural antisense transcript of p53. Within the 17.1.13 locus, two genes transcribed in opposite direction have been described: TP53 expressing 11 exons and WRAP53. Wrap53 and p53 transcripts anneal each other owing to the presence on both molecules of the proximal part of TP53 gene, including the noncoding exon 1 and part of the intron 1. This annealing stabilizes p53 mRNA and thus, increases p53 protein levels in cells.
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Recent results show that p53 could modulate these interactions through the expression of secreted factors. 34 In a recent report, Oren has shown that cancer cells, or their conditioned medium, reduced p53 response to cisplatin treatment in fibroblasts, as reflected by a attenuated accumulation of both p53 and p21. 35 In addition, the suppression by cancer cells of p53 response in adjacent fibroblasts was required for neoplastic progression. In his presentation, Oren (L2) presented new data on the impact of p53 expression in stromal cells on the growth of epithelial cancer cells. In mice, introduction of human PC3 prostate cancer cells in combination with p53-null mouse embryonic fibroblasts (MEFs) resulted in the development of tumors four fold larger than with wild-type p53 MEFs. Additionally, culturing of cancer cells in conditioned medium of p53-null MEFs increased their migration and invasion capabilities. Oren showed that these biological events depended upon stromal cell-derived factor 1, a chemokine repressed by p53 in MEFs. 36 These findings are in agreement with a previous study demonstrating a selection of stromal cells towards p53 loss in response to epithelial tumorigenesis, 37 thus suggesting that cancer cells may evolve to inhibit p53 suppressive activities in the tumor microenvironment, facilitating their growth and progression.
Mutant p53 GOF TP53 mutations are very common in cancer (www-p53. iarc.fr 38 ) and tend to cluster at some hot-spot codons, leading to point mutations rather than deletions. This led to the assumption that TP53 mutation not only abrogates tumor suppression functions of wild-type p53, but also gain new oncogenic activities exerted by mutant p53 (Figure 3 ). 39 
Diversity of mutant p53 targets
As mentioned above, studies by Rotter and colleagues (L8) identified a CGS regulated by p53 and Ras. The role of mutant p53 in regulating CGS was examined. Interestingly, different mutants exhibited different properties with respect to CGS regulation. A common conformational mutation within the L3 loop (p53 G245S ) affected neither CGS expression nor activity of H-Ras. The drastic conformational mutants with substitutions within the p53 Zn 2 þ binding domain (p53 R175H , p53 H179R ) showed comparable CGS expression levels and H-Ras activity as in p53 knock down cells, suggesting a complete loss of function with dominant negative effect of the mutant allele over the remaining wild-type allele. However, DNA contact mutants (p53 R248Q and p53
R273H
) showed significantly higher expression of the CGS, suggesting a GOF mechanism. This GOF effect was found to be mediated by NFkB, in agreement with previous reports showing that mutant p53 can exert GOF activities by stimulating NFkB activity. 40, 41 Finally, CGS expression was examined in lung, and head and neck tumors, where high CGS expression correlated with mutant p53 bearing tumors. This study suggests different abilities of the different p53 mutants to control the CGS and thus affect tumor development.
The transforming growth factor b (TGFb) signaling cascade has a dual role in carcinogenesis. Although in early stages TGFb acts to antagonize cancer progression, in later stages TGFb has pro-metastatic effects. 42 Although there is evidence that mutant p53 reduces the 43 data presented by Cordenonsi (S7) revealed an interplay between TGFb, mutant p53 and Ras during metastasis. TGFb, in concert with oncogenic Ras, induced the assembly of a mutant p53-p63 protein complex, which favors metastasis. 44 These data imply for a role for mutant p53 in late stage, pro-metastatic TGFb signaling.
Another role of mutant p53 in growth signaling was described by Bossi (S2). Building up on previous evidence of interactions between p53 and the mitogen-activated protein kinase pathway, he showed that mitogen-activated protein kinase-kinase 3, a specific activator of p38 mitogen-activating protein kinase, was transcriptionally regulated by p53. mitogen-activated protein kinase-kinase 3-depleted cells showed attenuated growth, although overexpression enhanced cell growth. 45 These findings suggest upregulation of mitogen-activated protein kinasekinase 3 expression represent a mechanism for mutant p53 GOF.
Two novel genes targeted by mutant p53 may participate in p53 GOF activities as described by Blandino (L12). These genes, inhibitor of DNA-binding 4 (ID4) and polo-like kinase-2 (Plk2), emerged from transcriptome analysis of H1299 cells expressing an inducible mutant p53 R175H . Inhibitor of DNA binding 4 is a member of a protein family which function as dominant-negative regulators of basic helix-loop-helix transcription factors involved in cell proliferation, differentiation and tumorigenesis. 46 siRNA-mediated depletion of p53 R175H severely impaired inhibitor of DNA binding 4 expression in proliferating tumor cells. Mutant p53 formed a complex with E2F1 on a specific region of inhibitor of DNA-binding 4 (ID4) promoter to upregulate expression, resulting in an increased angiogenic potential of mutant p53-expressing cancer cells. 47 The other target gene, Plk2 was targeted by mutant p53 following DNA damage. Plk2 interacted with and phosphorylated mutant p53, leading to a transcriptional feedback loop involving mutant p53 and Plk2 in response to DNA damage. Knocking down Plk2 increased cell sensitivity to DNA damaging, cytotoxic treatments.
Is GOF a consequence of unusual protein interactions?
The tumor suppressive promyelocytic leukemia protein (PML) is the major component of PML nuclear bodies implicated in apoptosis, cell proliferation and senescence. 48, 49 In humans, complete or partial loss of PML has been observed in many types of cancers, including breast, colon and prostate. 50 Although interconnections between wild-type p53 and PML have been described, 48 recent results of Haupt (L11) demonstrated that PML physically interacts with mutant p53 and enhances the transcriptional activity of mutant p53. 51 Cancer cells with mutant p53 presented attenuated growth following PML knock down. Furthermore, mutant p53 GOF activities, such as enhanced proliferation and colony formation, required PML. These finding suggest that the presence of both mutant p53 and PML may promote oncogenesis.
The prolyl isomerase Pin1 protein has been shown to bind phosphorylated S/T-P sites on protein substrates and to isomerize the intervening peptide bond leading to conformational changes that regulate protein activity and stability. 52 Studies by Del Sal (L10) revealed that Pin1 formed physical complexes with mutant p53 (as with wild-type p53 52, 53 ) and was required for mutant p53 to cooperate with oncogene-induced transformation in primary mouse fibroblasts. Moreover, in human breast cancer cell lines, Pin1 cooperated with mutant p53 to enhance tumor cell aggressiveness. These data indicate that Pin1 is required for activation of mutant p53 GOF.
Mouse models to explore mutant p53 functions Until recently, it was frequently assumed that mutant p53 was systematically stabilized in tumors owing to impaired Mdm2-mediated degradation. A study by Lozano (L20) challenged this concept. In a knock-in mice harboring the p53 R172H mutant (p53 54 These findings underline the need for careful assessment of the drug effects that stabilize wild-type p53, as these drugs may also stabilize mutant p53 and thus, promote carcinogenesis through mutant GOF activities.
Hollstein (L19) has generated over 200 immortalized MEF cell lines harboring mutant p53 using senescence bypass of embryonic fibroblasts from mice carrying a humanized p53 gene (human p53 knock-in). [55] [56] [57] As replicative senescence in hupki mouse cells exerts a selection pressure for outgrowth of cells with a mutated TP53 gene, these cells can be used to analyze the role of p53 modifications in escaping spontaneous or DNA damage-induced senescence. Although hupki embryonic fibroblasts (HUFs) immortalized at a similar rate as normal MEFs, hupki embryonic fibroblasts with S46A mutation escaped senescence more readily than their wildtype counterpart. Furthermore, when pre-senescent hupki embryonic fibroblasts were exposed to aristolochic acid, a mutagenic compound present in extracts of Aristolochia used in some traditional medications, emerging immortalized hupki embryonic fibroblast showed a high rate of A-T transversion mutations in TP53. 58 These mutations showed a remarkable correspondence with the mutations found in tumor of patients with Balkan endemic nephropathy, supporting the claim that this plant carcinogen has a direct role in the etiology of this regional disease. 59 Another mouse model of mutant p53 GOF was presented by Deppert (L3). In this model, transgenic mice carrying the SV40 early region were crossed with mice carrying mutant p53. 60 The use of the whey acidic protein promoter allowed for the targeted expression of both transgenes in the mammary epithelium. 61, 62 In this double transgenic model, binding of SV40-LT to p53
Understanding wild-type and mutant p53 activities in human cancer I Goldstein et al abrogates wild-type p53 0 s function. Crossing these mice with mice expressing mutant p53 R270H enhanced the formation of mammary tumors with more aggressive features and increased their metastatic potential. Loss of p53 led to activation of c-MET, an event that appeared essential for initiation and progression of mammary carcinomas. Consistent with these observations, a recent study has shown that miR-34a, a microRNA induced by p53, inhibited uveal melanoma cell proliferation and migration through downregulation of c-MET. 63 
Towards clinically effective p53 targeting drugs
In recent years, two drugs have been developed to activate wild-type p53 protein in tumors (Table 1 ). Nutlin-3 binds Mdm2 and induces accumulation of both p53 and Mdm2 leading to mitotic arrest, whereas RITA binds and stabilizes p53 while reducing Mdm2 expression, leading to apoptosis. However, the mechanisms by which these two drugs induce different responses remain unknown. Selivanova (L17) showed that RITA affected the transactivation of p53-dependent pro-apoptotic genes but not cell cycle arrest genes. 64 She presented two molecular mechanisms explaining this particular transactivation pattern (Figure 4a) . First, RITA inhibited p21 expression by increasing its proteasomal degradation and by downregulating hnRNP K, a cofactor of p53 transactivation, which is degraded in a Mdm2-dependent manner. In contrast to RITA, Nutlin-3 did not affect p21 and hnRNP K expression nor did it induce the transactivation of proapoptotic genes. Second, at high levels, RITA induced both expression of pro-apoptotic genes and downregulation of oncogenes and pro-survival factors.
64 Soddu (L16) reported another molecular mechanism that may explain the different response induced by RITA and Nutlin-3. She demonstrated that apoptosis-inducing doses of adriamycin resulted in the accumulation of homeodomain-interacting protein kinase 2, which is responsible for the phosphorylation of S46 of p53. 65 In contrast, doses that induced mitotic arrest but not apoptosis were associated with a decrease of both homeodomain-interacting protein kinase 2 expression and S46 phosphorylation. The decrease in homeodomain-interacting protein kinase 2 levels was owing to its degradation mediated by Mdm2, suggesting the different responses elicited by Nutlin-3 and RITA may be owing to their different effects on Mdm2-dependent degradation of homeodomain-interacting protein kinase 2. 66 Screening of drugs and peptides libraries has proved a useful approach to identify drugs that specifically target mutant p53 but not wild-type form (Table 1) . Bisso (S5) isolated five peptide aptamers (PAs) interacting specifically with p53 mutants. He demonstrated that PAs had a higher affinity for unfolded conformational mutant p53 than for wild-type p53 or contact mutants, which conserve the overall protein architecture. Interaction with PAs inhibited mutant p53 transcriptional activity and induced apoptosis in tumor cell lines expressing mutant p53. 67 Three-dimensional models of mutant p53-PAs complexes indicated that PAs interacted with the proximal part of the p53 core domain via three important residues (T102, L130 and N131). Another approach was presented by Joerger, from the group of A. Fersht (L13), to identify compounds which target the hot-spot mutant p53 Y220C and restore its wild-type activity by stabilizing the protein structure. Mutation at codon 220 is one of the most common mutation outside the DNA binding surface of p53 and it has the particularity to affect a crevice amenable to the binding of designed small chemicals. Using in silico analyses, Fersht group identified a family of drugs, PhiKan, that specifically interact with mutant p53 Y220C and restored wild-type conformation. 68 Several small drugs have been shown to restore wildtype p53 activity leading to apoptosis, among which is PRIMA-1 (Table 1) . However, the mechanisms responsible for this restoration are still unknown. Wiman (L18) reported that intracellular metabolization of PRIMA-1 generates a thiol reactive intermediate that induces alkylation of cysteines located in the p53 core domain. This chemical modification, in turn, appears to facilitate the restoration of wild-type p53 conformation and DNA binding activity. 69 The affinity of PRIMA-1 appeared to depend on the degree of p53 unfolding, explaining the selectivity of PRIMA towards mutant p53. Re-introduction of PRIMA-1-treated p53 R175H in p53-null cells was correlated with upregulation of BAX and caspase activation leading to apoptosis (Figure 4b ).
These studies support the notion that mutant p53 is a 'druggable' target in order to restore wild-type function. However, these compounds still need to be assessed for their functional and biological effects. TP53 mutations have generally been associated with poor prognosis and poor response to treatment in several types of cancers. In squamous cell carcinomas of the head and neck, TP53 mutations are found in the majority of the cases and are associated with poor survival after surgery. Myers (L22) described the squamous cell carcinomas of the head and neck cell line Tu138, which carries the p53 P151S mutation that made these cells resistant to cell death induced by loss of anchorage (anoikis). He demonstrated that expression of this mutant in anoikissensitive cells led to downregulation of PUMA and NOXA, inducing resistance to anoikis and enhanced tumorigenicity in an orthotopic nude mouse model of oral cancer.
In breast cancers, TP53 mutations are found in about 25% of the cases and are associated with poor prognosis and resistance to doxorubicin treatment. 70 Expression signature of mutant TP53 status have been described that include genes involved in the estrogen receptor pathway and in the control of cell proliferation, 71, 72 suggesting a close link between p53 and estrogen receptor pathways.
To investigate this hypothesis, Olivier and colleagues (L23) analyzed the crosstalks between p53 and estrogen receptor pathways in cell responses to estrogens, antihormone or chemotherapy treatments. They showed that estrogens levels could modulate both wild-type and mutant p53 protein levels. Estrogen deprivation compromised p53 response to DNA damage by reducing p53 protein steady-state levels. 73 These results are in line with previous observations that were made in a clinical series, where a larger effect of TP53 mutation status was found for patient survival in cases with progesterone receptor positive status, a marker of a functional estrogen receptor pathway. How estrogens may affect p53 mutant activities remain to be addressed. Additionally, it was shown that in TP53 mutated cells, the antiestrogen tamoxifen had proliferative effects, although it had expected antiproliferative effects in TP53 wild-type cells (Ferna´ndez-Cuesta 2010, Int J Cancer, in press). It remains to be determined which activities of mutant p53 may be responsible for this effect.
TP53 mutations are very frequent is lung cancer, in particular in smokers. Hainaut (L24) reported that, in a large randomized therapeutic clinical trial, International Adjuvant Lung cancer Trial, n ¼ 783 aimed at assessing the benefits of cisplatin-based adjuvant therapy in Understanding wild-type and mutant p53 activities in human cancer I Goldstein et al completely resected non-small cell lung carcinoma (NSCLC) patients, TP53 status had no prognostic value at 8 years of follow-up. However, TP53 status was a significant predictor of response to therapy, in particular in squamous cell carcinoma. Although, wild-type TP53 did not predict a better response to therapy, mutant TP53 predicted a decreased survival and disease-free interval in patients receiving chemotherapy. Thus, the presence of mutant p53, although having no significant effect on the course of the disease in the absence of adjuvant therapy, significantly reduced the survival of patients upon treatment. These results are the first evidence for GOF in a clinical setting. Polymorphisms in genes of the TP53 pathway, such as MDM2 SNP309 and p53R72P have been shown to have modifier effects on the penetrance of TP53 germline mutations in Li-Fraumeni's syndrome. 74, 75 Marcel (S4) analyzed another common TP53 polymorphism, TP53 PIN3, a 16 base pair duplication located in intron 3 (rs17878362; A1, non-duplicated allele; A2, duplicated allele) that is present at an allele frequency of 0.2 in Caucasians. In a cohort of Brazilian LFS, she found that TP53 PIN3 was associated with a difference of 19.0 years in the mean age at first diagnosis in TP53 mutation carriers (n ¼ 25; A1A1: 28.0 years; n ¼ 7; A1A2: 47.0 years; P ¼ 0.01). As a result, cancer occurrence before age of 35 years was exclusively detected in homozygotes of the more frequent allele (A1). 76 These results highlight the modifier effect of TP53 intronic polymorphisms and further suggest that not only the type and effect of mutation, but also the nature of the affected haplotype and of the remaining wild-type haplotype, are critical to understand the full impact of mutant p53 in cancer.
Conclusion and perspectives
In all, 10 years of research focusing on mutant p53 have yielded remarkable progress in understanding their specific functions. It is now clear that GOF mutant p53 is not a single and generic property. In a manner reminiscent of wild-type p53, mutant p53 is a multifunctional factor, of which the effects may differ according to the cancer cells in which the mutation occurs. Two main avenues for further research may be identified. First, accumulation of mutant p53 at higher levels than those normally found in healthy cells, may allow mutant proteins to interact with a larger panel of DNA and proteins than wild-type p53. Second, it should be considered that mutant p53 may exert particular effects depending on its structure and its affinity for defined DNA or protein targets. The respective importance of this dosage effect and these specific structural effects induced by the mutation should be further investigated, but a combination of these two properties may account for the wide diversity of mutant p53 effects.
It is becoming clear that all cancers have a defective p53 pathway, either by TP53 mutation or by deregulation of another determinant of the p53 pathway. Despite this increased complexity, the field of mutant p53 research is now swiftly moving towards translation in the clinics. It is now technically possible to assess TP53 mutation status in large clinical studies and to combine mutation identification with expression studies of gene and micro-RNA, paving the way to the definition of 'mutant p53 molecular profiles'. Such profiles may provide extremely precise predictors of disease outcomes and of responses to therapy. Furthermore, a whole range of small drugs is available, which act on different aspects of mutant p53 activities. These drugs are now ready to move into clinical trials, either alone or in combination with classical therapeutic approaches. In the next 10 years, such molecules are expected to contribute in an important way to the large panel of specific drugs that will be required to deliver the promises of evidence-based and personalized medicine.
